Contract ValueSOPH is more than doubling the average contract value on newer deals signed, which should drive up ASPs and GMs.
Customer GrowthSOPH is signing record numbers of new customers, indicating strong growth potential.
Revenue And MarginSOPH sees signs of a recovery building in biopharma, which will mark an inflection point in revenue and margin.